Novavax said on Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses ...

Meanwhile, during the WSJ event in Davos this week, Pfizer’s Bourla also took aim at the Trump administration’s moves to cut ...

Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV specialist ViiV Healthcare in a deal that ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Robert F. Kennedy’s position on vaccines is profoundly "anti-science" and making progress would require a new health secretary, Pfizer Chief Executive Albert Bourla said Wednesday. “I have very ...

Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Pfizer will relinquish its stake in ViiV Healthcare in a deal valued at just over $2.1 billion that ramps up Shionogi's ...

Madrigal Pharma is reheating a drug for metabolic dysfunction-associated steatohepatitis (MASH) put on ice by Pfizer, hoping ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Any believers in UPS who buy now can enjoy a generous dividend payment every quarter while waiting for a turnaround. Given ...

Both Ford and Pfizer have very attractive dividend yields.